Clario appoints Dr. Rod MacKenzie as Chairman of the Board of Directors

– USA, PA –  Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry, today announced the appointment of Dr. Rod MacKenzie (CMG, Ph.D.). as their new Chairman of the Board of Directors.

“I am excited to join the team at Clario,” said Dr. MacKenzie. “The company has a strong track record in the industry of putting science at the heart of clinical research. Clario has extensive depth in cardiac safety, respiratory, imaging, and eCOA services across therapeutic areas, and is a pioneer in remote data collection. I am proud to now be a part of that journey, working with the Board and the management team to deliver innovation that supports the development of life-saving medicines for patients.”

About Dr. MacKenzie

Dr. MacKenzie has had a distinguished career in pharmaceutical R&D, most recently holding the position of CDO and EVP at Pfizer Inc. He led the company’s worldwide development operations, including clinical development and regulatory affairs. Alongside other positions, he was previously Chair of the Board of TransCelerate – an industry-wide non-profit focused on accelerating clinical research, and was a member of the Executive Committee for Clinical Trials Transformation Initiative, a public-private partnership co-founded by the FDA and Duke University to develop and drive practices that will increase the quality and efficiency of clinical trials.

About Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech, and medical device partners. Across decentralized, hybrid, and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s global team of science, technology and operational experts has helped deliver over 24,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than five million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.